Piramal Pharma invests over Rs 69 crore to expand its API capability
The new wing at the Riverview site is dedicated to the production of HPAPIs with low occupational exposure levels (OELs), Piramal Pharma Solutions said in a statement.
New Delhi: Piramal Pharma Solutions Thursday said it has invested USD 10 million (around Rs 69 crore) to expand its high-potency active pharmaceutical ingredients (HPAPIs) capability in its Riverview facility in the US.
The new wing at the Riverview site is dedicated to the production of HPAPIs with low occupational exposure levels (OELs), Piramal Pharma Solutions said in a statement.
Read Also: Piramal partner Slate Run Pharma launches Cinacalcet Hydrochloride tablets in US
Piramal Pharma Solutions Chief Executive Officer Vivek Sharma said: "We are one of only a few companies in the contract development and manufacturing market that have the capability to produce HPAPIs at such low OELs."
The expansion enhances the company's ability to serve the growing antibody-drug conjugate market, the statement said.
Read Also: Panacea Biotec Bail out: Piramal, Bain offer Rs 992 crore deal
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd